EUVIMEDEUVIMED entdecken
Crossref

Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events

Cosmo Godino, Riccardo Mazza, Carlo Gaspardone, Alessia Minerva, Rachele Sena, Gianmarco Cozzani, Anna Salerno, Michela Cera, Massimo Slavich, Leila Anna De Lorenzo, Giulio Leo, Giulia Nemola und 6 weitere

Journal of Thrombosis and Haemostasis · 2025-11 · 23 (11) · 3515-3526

DOI: 10.1016/j.jtha.2025.06.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-11. Verfasst von Cosmo Godino und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Heart Valve Center, IRCCS San Raffaele Scientific Institute and Vita-Salute University, Milan, Italy. Electronic address: cosmogodin…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Thromboembolism, Hemorrhage, Factor Xa Inhibitors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Direct oral anticoagulants (DOACs) are standard therapy to prevent thromboembolic events in nonvalvular atrial fibrillation (NVAF) and are generally used without routine monitoring of plasma anti-Xa or anti-IIa levels. OBJECTIVES: This study aimed to assess whether plasma levels of anti-Xa or anti-IIa at the time of presentation are associated with acute thromboembolic or bleeding events in DOAC-treated patients with NVAF. METHODS: This prospective case-control study included consecutive long-term DOAC-treated patients with NVAF presenting to a European emergency department with acute thromboembolic or bleeding events (cases), or for other medical reasons (controls). DOAC plasma levels were measured using drug-specific chromogenic anti-Xa assays (rivaroxaban, apixaban, and edoxaban) or diluted thrombin time (dabigatran), categorized into quartiles, and analyzed according to event type. RESULTS: Among 1794 patients (mean age 82 years, 49% female), 8% had thromboembolic events, 15% bleeding events, and 77% other presentations. DOAC treatment included apixaban (45%), dabigatran (17%), rivaroxaban (17%), and edoxaban (21%). Thromboembolic events were more common in patients with DOAC plasma levels in the first quartile (Q1: 50% vs 26%; P < .001), while bleeding events were more common in the fourth quartile (Q4: 46% vs 23%; P < .001). Q1 levels were associated with increased odds of thromboembolic events (OR, 2.04; 95% CI, 1.36-3.08), and Q4 levels with bleeding events (OR, 2.05; 95% CI, 1.49-2.82). CONCLUSION: DOAC plasma levels show substantial interindividual variability and are associated with acute thromboembolic and bleeding events. These observations may help generate hypotheses for future studies aimed at better defining the role of DOAC plasma monitoring in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationThromboembolismHemorrhageFactor Xa InhibitorsPyridinesAnticoagulantsHumansFemaleMaleAgedAged, 80 and overProspective StudiesPyridonesRivaroxabanAdministration, OralPyrazolesDabigatranCase-Control StudiesThiazolesDrug MonitoringRisk FactorsTime FactorsTreatment OutcomeEurope

Stichwörter der Autor:innen

atrial fibrillationbleedingdirect oral anticoagulantsplasma level measurementsstroke

Substanzen

apixabanPyridonesRivaroxabanFactor Xa InhibitorsPyrazolesedoxabanDabigatranPyridinesThiazolesAnticoagulants

Autor:innen und Institutionen

  • Cardiology Unit, Heart Valve Center, IRCCS San Raffaele Scientific Institute and Vita-Salute University, Milan, Italy. Electronic address: cosmogodino@gmail.com.
  • San Raffaele Vita-Salute University, Milan, Italy.
  • Cardiology Unit, Heart Valve Center, IRCCS San Raffaele Scientific Institute and Vita-Salute University, Milan, Italy.
  • Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy.
  • Coagulation Service & Thrombosis Research Unit, Scientific Institute San Raffaele, Milano, Italy.

Zitieren

APA

Godino, C., Mazza, R., Gaspardone, C., Minerva, A., Sena, R., Cozzani, G., Salerno, A., Cera, M., Slavich, M., De Lorenzo, L. A., Leo, G., Nemola, G., Fattorini, A., Crippa, L., Della Valle, P., Margonato, A., D'Angelo, A., & 4Levels Study investigators (2025). Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events. Journal of Thrombosis and Haemostasis, 23(11), 3515-3526. https://doi.org/10.1016/j.jtha.2025.06.031

Vancouver

Godino C, Mazza R, Gaspardone C, Minerva A, Sena R, Cozzani G, et al. Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events. Journal of Thrombosis and Haemostasis. 2025;23(11):3515-3526. doi:10.1016/j.jtha.2025.06.031

BibTeX
@article{Godino2025,
  author = {Godino, Cosmo and Mazza, Riccardo and Gaspardone, Carlo and Minerva, Alessia and Sena, Rachele and Cozzani, Gianmarco and Salerno, Anna and Cera, Michela and Slavich, Massimo and De Lorenzo, Leila Anna and Leo, Giulio and Nemola, Giulia and Fattorini, Annalisa and Crippa, Luciano and Della Valle, Patrizia and Margonato, Alberto and D'Angelo, Armando and 4Levels Study investigators, 4Levels Study investigators},
  title = {Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {11},
  pages = {3515--3526},
  doi = {10.1016/j.jtha.2025.06.031}
}
Kostenlos starten →